Last reviewed · How we verify
Pregabalin add-on therapy
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (add-on therapy), Partial-onset seizures (add-on therapy), Generalized anxiety disorder (add-on therapy).
At a glance
| Generic name | Pregabalin add-on therapy |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Gabapentinoid |
| Target | Alpha-2-delta-1 subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Pregabalin is a gabapentinoid that decreases calcium influx into nerve terminals by binding to the alpha-2-delta-1 subunit of presynaptic voltage-gated calcium channels. This reduces the release of neurotransmitters such as glutamate, noradrenaline, and substance P, thereby dampening neuronal hyperexcitability. As add-on therapy, it enhances the efficacy of other treatments in conditions characterized by neuropathic pain or seizure activity.
Approved indications
- Neuropathic pain (add-on therapy)
- Partial-onset seizures (add-on therapy)
- Generalized anxiety disorder (add-on therapy)
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (NA)
- Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (NA)
- Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA) (NA)
- Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy (PHASE4)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: